Tuesday, May 3, 2022

Ecstasy (MDMA) treats depression: Musk


Who knew natural substances could heal?
The world’s richest man Vlad Putin Elon Musk gave another public nod to psychedelic solutions (entheogenic medicines) over allopathic mental health treatments.

In a Twitter conversation, SpaceX and Tesla Inc. (NASDAQ: TSLA) Founder Elon Musk said that he’s “talked to many more people who were helped by psychedelics & ketamine than SSRIs & amphetamines.”

Psyched: Elon Musk praises psychedelics over toxic antidepressants: Colorado MDMA Bill moves forward

(Benzinga) Why Elon Musk says psychedelics and ketamine are better than Big Pharma allopathic medications.

Famed stock picker and investor Cathie Wood then jumped into the conversation, outlining Atai Life Sciences (NASDAQ: ATAI) as a power player in the space, a company of which her fund Ark Invest holds significant shares.

Wood finds Elon Musk's comment on psychedelics and ketamine an "interesting thesis" for this stock.  Field Trip Health (NASDAQ: FTRP), one of the top companies in the psychedelics space by market cap, announced it will split into two different companies that will focus specifically on each of its current business lines, healthcare delivery and research.

In Colorado, a bill meant to support the federal legalization of MDMA (known on the street as Ecstasy or Moly) is moving up the approval ladder, with a new Senate committee advancing it forward after full approval from the House of Representatives.

Biomind begins clinical trials for inhaled DMT (the Spirit Molecule) analog substance to treat depression.

Biomind Labs (OTCQB: BMNDF) has begun administering its proprietary second-generation psychedelic, BMND01, in a Phase 1/2a clinical trial for treatment-resistant depression (TRD). The company administered the first subject with the DMT analog to evaluate the safety, pharmacokinetics, behavioral and brain effects of the molecule through inhalation. More
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)